Kratom compound MG001 enters first human safety trial
NCT ID NCT07204171
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 32 times
Summary
This early-stage study tests MG001, a compound from the kratom plant, in 32 healthy adults for the first time. The goal is to see if it is safe, how well people tolerate it, and how the body processes it. Participants receive a single dose of MG001 or a placebo and are closely monitored for several days. This research gathers essential safety data before any future studies on opioid withdrawal can begin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND TOLERABILITY IN HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Kansas
Overland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.